Renibus Therapeutics has completed subject enrolment for the randomised Phase III PROTECT trial, assessing RBT-1 (stannic protoporfin/iron sucrose) in minimising post-operative complication risk in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback